Pacer Advisors Inc. Increases Stock Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Pacer Advisors Inc. boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 12.1% in the third quarter, HoldingsChannel.com reports. The fund owned 40,985 shares of the biopharmaceutical company’s stock after purchasing an additional 4,433 shares during the period. Pacer Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $4,014,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at about $28,000. Redhawk Wealth Advisors Inc. purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at about $29,000. Ossiam purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at about $32,000. Thor Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals in the 1st quarter valued at about $34,000. Finally, Capital Bank & Trust Co boosted its stake in shares of Alexion Pharmaceuticals by 355.9% in the 2nd quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 210 shares during the period. Institutional investors own 93.13% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Morgan Stanley cut their target price on Alexion Pharmaceuticals from $177.00 to $170.00 and set an “overweight” rating on the stock in a research report on Friday. Piper Jaffray Companies set a $180.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 6th. Stifel Nicolaus reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Friday, August 30th. Credit Suisse Group cut their target price on Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Finally, BidaskClub raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $159.76.

ALXN opened at $99.25 on Friday. The firm has a market cap of $22.25 billion, a price-to-earnings ratio of 14.00, a price-to-earnings-growth ratio of 0.90 and a beta of 1.67. Alexion Pharmaceuticals, Inc. has a 52 week low of $92.56 and a 52 week high of $141.86. The business’s 50 day moving average is $103.91 and its two-hundred day moving average is $120.01. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.13 by $0.51. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The firm’s revenue was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.07 earnings per share. Equities analysts expect that Alexion Pharmaceuticals, Inc. will post 9.05 EPS for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: Economic Reports

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.